Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Long-Term Results and Characteristics of Pleural Effusion in Late Chronic Phase Chronic Myeloid Leukemia Patients at Dasatinib Therapy after Imatinib Failure

Galina Gusarova, MD PhD, Anastasia Bykova, MD, Alexandra Vorontsova, MD PhD, Sergey Kuznetsov, MD, Oleg Shukhov, MD, Ekaterina Chelysheva, MD PhD, Olga Lazareva, MD PhD, Svetlana Goryacheva, MD PhD, Tatyana Ivanova, MD PhD, Anna G. Turkina, MD PhD

Blood (2015) 126 (23): 5141.

https://doi.org/10.1182/blood.V126.23.5141.5141

Published: 2015

Journal Articles

Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study

Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Marco Aurelio Salvino, MD PhD, Ong Tee Chuan, MD, Alaa Elhaddad, MD PhD, Kudrat Abdulkadyrov, MD PhD, Jake Shortt, MD, Hang Quach, MD, Carolina Pavlovsky, MD, Vernon J. Louw, MBChB, M.MD FCP(SA), PhDHPE), Lee-Yung Shih, MD, Anna G. Turkina, MD PhD, Luis Meillon, MD, Yu Jin, MS, Sadhvi Khanna, MS, Darshan Dalal, MD PhD MPH, Jeffrey H. Lipton, MD PhD

Blood (2015) 126 (23): 344.

https://doi.org/10.1182/blood.V126.23.344.344

Published: 2015

Journal Articles

Efficacy and Safety of Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTxtnd Interim Analysis

Timothy P. Hughes, MD, Eduardo Ciliao Munhoz, MD, Alaa Elhaddad, MD PhD, Ong Tee Chuan, MD, Kudrat Abdulkadyrov, MD, Jake Shortt, MD, Hang Quach, MD FRACP, FRCPA, MBBS, Carolina Pavlovsky, MD, Vernon J. Louw, MBChB, M.MD FCP(SA), PhDHPE), Luis Meillon, MD, Lee-Yung Shih, MD Professor, Anna G. Turkina, MD PhD, Jonathan Hwang, PharmD, MBA, Prasanna Kumar Nidamarthy, Darshan Dalal, MD PhD MPH, Jeffrey H. Lipton, PhD MD

Blood (2014) 124 (21): 4542.

https://doi.org/10.1182/blood.V124.21.4542.4542

Published: 2014

Journal Articles

Challenge to Use the Interval Censorship Estimators for Time to Response Evaluation By Data from Chronic Myeloid Leukemia Registry

Sergey M. Kulikov, PhD, Irina A. Tischenko, Ekaterina Yu. Chelysheva, MD PhD, Olga V. Lazareva, PhD, Anna G. Turkina, MD PhD

Blood (2014) 124 (21): 3140.

https://doi.org/10.1182/blood.V124.21.3140.3140

Published: 2014

Journal Articles

Incidence of CML in Europe—a Comparison of 19 European Countries with US SEER Data

Blood (2014) 124 (21): 3145.

https://doi.org/10.1182/blood.V124.21.3145.3145

Published: 2014

Journal Articles

Prognostic Value of the Rate of BCR-ABL Decline for Patients with Chronic Myelogenous Leukemia in Chronic Phase on Tyrosine Kinase Inhibitors Treatment

Blood (2014) 124 (21): 3148.

https://doi.org/10.1182/blood.V124.21.3148.3148

Published: 2014

Journal Articles

Baseline Characteristics of CML Patients Accross Europe - Comparing Real-World Patients with Patient Collectives Included in Clinical Trials

Blood (2014) 124 (21): 3160.

https://doi.org/10.1182/blood.V124.21.3160.3160

Published: 2014

Journal Articles

Polymorphism of UGT1A1 and Frequency of Hyperbilirubinemia in Patients with Chronic Myeloid Leukemia Treated By Nilotinib

Anastasia Bykova, MD, Adhamjon Abdullaev, MD PhD, Galina Gusarova, MD PhD, Ekaterina Chelysheva, MD PhD, Svetlana Treglazova, MD, Svetlana Smirnova, MD, Anna G. Turkina, MD PhD

Blood (2014) 124 (21): 5538.

https://doi.org/10.1182/blood.V124.21.5538.5538

Published: 2014

Journal Articles

Treatment Cessation in Chronic Myeloid Leukemia As a Part of Treatment Process: Toxicity Determined and Active Stop of Tyrosine Kinase Inhibitors

Anna G. Turkina, MD PhD, Ekaterina Yu. Chelysheva, MD PhD, Vasiliy Shuvaev, Galina Gusarova, MD PhD, Anastasia Bykova, MD, Olga V. Lazareva, PhD, Oleg Shukhov, MD, Adham Abdullaev, MD PhD, Irina Martynkevich, Kudrat Abdulkadyrov, MD

Blood (2014) 124 (21): 5518.

https://doi.org/10.1182/blood.V124.21.5518.5518

Published: 2014

Journal Articles

Is Superinstability Of Karyotype Of Acute Myeloid Leukemia “Relic Radiation From Big Bang” Of Chromosome Homeostasis On MDS Stage?

Alexander S. Luchinin, MD, Anna G. Turkina, MD, PhD, Vanik A. Ovsepyan, PhD

Blood (2013) 122 (21): 4999.

https://doi.org/10.1182/blood.V122.21.4999.4999

Published: 2013

Journal Articles

Long-Term Results and Adverse Events Of Second Line Nilotinib Therapy After Imatinib Failure In Patients With Chronic Myeloid Leukemia In Chronic Phase In Clinical Practice

Anastasia Bykova, MD, Galina Gusarova, MD, PhD, Ekaterina Yu. Chelysheva, MD, PhD, Anna G. Turkina, MD, PhD,

Blood (2013) 122 (21): 5181.

https://doi.org/10.1182/blood.V122.21.5181.5181

Published: 2013

Journal Articles

ENESTxtnd: Impact Of Nilotinib Dose Re-Escalation In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)

Jeff H. Lipton, PhD, MD, Luis Meillon, MD, Vernon Louw, MD, Carolina Pavlovsky, MD, Lee-Yung Shih, MD, Yu Jin, Sandip Acharya, Richard C. Woodman, Timothy P. Hughes, MD, Anna G. Turkina, MD, PhD

Blood (2013) 122 (21): 4009.

https://doi.org/10.1182/blood.V122.21.4009.4009

Published: 2013

Journal Articles

EUTOS Score Is Also Valid in CML Patients Not Involved in Clinical Studies

Verena S Hoffmann, MA., Jiri Mayer, MD, Anna G. Turkina, MD, PhD, Andrzej Hellmann, MD, Karel Indrak, MD, Prof., Juan Luis Steegmann, MD, Andrey Zaritskey, MD, Adriana Colita, MD, Doris Lindoerfer, Dipl.-Inf., Michele Baccarani, MD

Blood (2012) 120 (21): 3759.

https://doi.org/10.1182/blood.V120.21.3759.3759

Published: 2012

Journal Articles

First Results of Russian Multicenter Population Base Study of the Incidence of Chronic Myeloid Leukemia

Sergey M. Kulikov, Ph.D., Olga Yu. Vinogradova, MD, PhD, Ekaterina Yu. Chelysheva, PhD, Marya V. Galayko, Irina A. Titshenko, Eduard G. Gendgan, Olga M. Senderova, PhD, Valentyna M. Pepelyaeva, Sergey V. Meresy, Alexander S. Luchinin, MD, Vanik A. Ovsepyan, PhD, Galina I. Milutina, PhD, Lubov V. Gavrilova, PhD, Ludmila B. Avdeeva, Anna G. Turkina, MD, PhD

Blood (2012) 120 (21): 4431.

https://doi.org/10.1182/blood.V120.21.4431.4431

Published: 2012

Journal Articles

Clinical Significance of Additional Chromosomal Abnormalities In Ph-Positive and Ph-Negative Cells In Patients with Chronic Myeloid Leukemia Treated by Tyrosine Kinase Inhibitors

Anna G. Turkina, MD, PhD, Olga Vinogradova, PhD, Alexandra Vorontsova, PhD, Ekaterina Chelysheva, PhD, Olga Lazareva, PhD, Galina Gusarova, PhD, Elena Aseeva, PhD, Nina Khoroshko, MD, PhD

Blood (2011) 118 (21): 1683.

https://doi.org/10.1182/blood.V118.21.1683.1683

Published: 2011

Journal Articles

Nilotinib Shows Safety and Efficacy in Older Patients (≥ 65 years) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Comparable with That in Younger Patients with Chronic Myeloid Leukemia in Chronic Phase: Results From ENESTnd,

Richard A. Larson, MD, Udomsak Bunworasate, MD, Anna G. Turkina, MD, PhD, Stuart L. Goldberg, MD, Pedro Dorlhiac-Llacer, MD, Jose L. Lopez, MD, Hagop M. Kantarjian, Giuseppe Saglio, MD, Andreas Hochhaus, MD, Albert Hoenekopp, MD, Rick E. Blakesley, PhD, Richard Yu, Neil J. Gallagher, MD, PhD, Richard E. Clark, MD, Timothy P. Hughes, MD, MBBS

Blood (2011) 118 (21): 3768.

https://doi.org/10.1182/blood.V118.21.3768.3768

Published: 2011

Journal Articles

Results of Tyrosine Kinase Inhibitors (TKI) Therapy of Patients (Pts) with Chronic Myeloid Leukemia (CML) In Clinical Practice Analysed In the Frame of International Research Project EUTOS In Russian Federation

Anna G. Turkina, MD, PhD, Sergey Kulikov, Kudrat Abdulkadirov, Sergey Kutsev, MD, PhD, Anatoly Golenkov, MD, Valentina Ivanova, Tatiana Pospelova, MD, PhD, Tatiana Konstantinova, Olga Lazareva, PhD, Nina Khoroshko, MD, PhD

Blood (2011) 118 (21): 4447.

https://doi.org/10.1182/blood.V118.21.4447.4447

Published: 2011

Journal Articles

Efficacy and Safety of Nilotinib In Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (Pts) with Type 2 Diabetes In the ENESTnd Trial.

Giuseppe Saglio, MD, PhD, Richard A. Larson, MD, Timothy P. Hughes, MD, MBBS, Surapol Issaragrisil, MD, Anna G. Turkina, MD, PhD, David Marin, MD, FRCP, Maria Zanichelli, MD, Hirohiko Shibayama, MD, PhD, Matt E. Kalaycio, MD, Francoise Rigal-Huguet, MD, Neil J. Gallagher, MD, PhD, Marcia Kayath, MD, Ming Zheng, PhD, Hagop Kantarjian, MD, Andreas Hochhaus, MD

Blood (2010) 116 (21): 3430.

https://doi.org/10.1182/blood.V116.21.3430.3430

Published: 2010

Journal Articles

Efficacy and Safety of Bosutinib (SKI-606) in Patients with Chronic Phase (CP) Ph+ Chronic Myelogenous Leukemia (CML) with Resistance or Intolerance to Imatinib.

Jorge Cortes, MD, Hagop M Kantarjian, Dong- Wook Kim, MD, PhD, H. Jean Khoury, MD, FACP, Anna G. Turkina, MD, Zhi-Xiang Shen, MD, Tim H Brummendorf, MD, Mammen Chandy, MD, Steven Arkin, MD, Carlo Gambacorti-Passerini, MD

Blood (2008) 112 (11): 1098.

https://doi.org/10.1182/blood.V112.11.1098.1098

Published: 2008

NARROW

Long-Term Results and Characteristics of Pleural Effusion in Late Chronic Phase Chronic Myeloid Leukemia Patients at Dasatinib Therapy after Imatinib Failure

Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study

Efficacy and Safety of Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTxtnd Interim Analysis

Challenge to Use the Interval Censorship Estimators for Time to Response Evaluation By Data from Chronic Myeloid Leukemia Registry

Incidence of CML in Europe—a Comparison of 19 European Countries with US SEER Data

Prognostic Value of the Rate of BCR-ABL Decline for Patients with Chronic Myelogenous Leukemia in Chronic Phase on Tyrosine Kinase Inhibitors Treatment

Baseline Characteristics of CML Patients Accross Europe - Comparing Real-World Patients with Patient Collectives Included in Clinical Trials

Polymorphism of UGT1A1 and Frequency of Hyperbilirubinemia in Patients with Chronic Myeloid Leukemia Treated By Nilotinib

Treatment Cessation in Chronic Myeloid Leukemia As a Part of Treatment Process: Toxicity Determined and Active Stop of Tyrosine Kinase Inhibitors

Is Superinstability Of Karyotype Of Acute Myeloid Leukemia “Relic Radiation From Big Bang” Of Chromosome Homeostasis On MDS Stage?

Long-Term Results and Adverse Events Of Second Line Nilotinib Therapy After Imatinib Failure In Patients With Chronic Myeloid Leukemia In Chronic Phase In Clinical Practice

ENESTxtnd: Impact Of Nilotinib Dose Re-Escalation In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)

EUTOS Score Is Also Valid in CML Patients Not Involved in Clinical Studies

First Results of Russian Multicenter Population Base Study of the Incidence of Chronic Myeloid Leukemia

Clinical Significance of Additional Chromosomal Abnormalities In Ph-Positive and Ph-Negative Cells In Patients with Chronic Myeloid Leukemia Treated by Tyrosine Kinase Inhibitors

Nilotinib Shows Safety and Efficacy in Older Patients (≥ 65 years) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Comparable with That in Younger Patients with Chronic Myeloid Leukemia in Chronic Phase: Results From ENESTnd,

Results of Tyrosine Kinase Inhibitors (TKI) Therapy of Patients (Pts) with Chronic Myeloid Leukemia (CML) In Clinical Practice Analysed In the Frame of International Research Project EUTOS In Russian Federation

Efficacy and Safety of Nilotinib In Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (Pts) with Type 2 Diabetes In the ENESTnd Trial.

Efficacy and Safety of Bosutinib (SKI-606) in Patients with Chronic Phase (CP) Ph+ Chronic Myelogenous Leukemia (CML) with Resistance or Intolerance to Imatinib.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only